The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety analysis of a phase III randomized trial comparing FOLFOX + Bevacizumab vs FOLFOXIRI + Bevacizumab as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 circulating tumor cells (CTCs) (VISNÚ-1 TTD TRIAL).
 
A. Gomez
No Relationships to Disclose
 
Jose María Vieitez
No Relationships to Disclose
 
Silvia Gil
No Relationships to Disclose
 
Antonieta Salud Salvia
No Relationships to Disclose
 
Begoña Graña Suárez
No Relationships to Disclose
 
Pilar Garcia Alfonso
No Relationships to Disclose
 
Eva Martínez de Castro
No Relationships to Disclose
 
Guillermo Alfonso Quintero Aldana
No Relationships to Disclose
 
Juan J Reina
No Relationships to Disclose
 
Encarnación González Flores
No Relationships to Disclose
 
Mercedes Salgado Fernández
No Relationships to Disclose
 
Mercedes Rodríguez Garrote
No Relationships to Disclose
 
Ma. José Flor Oncala
No Relationships to Disclose
 
Maria Jose Safont
No Relationships to Disclose
 
Adelaida La Casta Munoa
No Relationships to Disclose
 
Rafael Lopez
No Relationships to Disclose
 
Guillot Monica
No Relationships to Disclose
 
Beatriz García-Paredes
No Relationships to Disclose
 
Eduardo Diaz-Rubio
No Relationships to Disclose
 
Enrique Aranda
Consulting or Advisory Role - Amgen; Bayer; Celgene; Merck; Roche; Sanofi